2nd April 2019
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. The trial used a treatment combination of ADI-PEG20, pemetrexed and cisplatin, which showed encouraging efficacy in patients with recurrent high-grade gliomas (HGGs), a disease for which little progress has been made over the last few decades.
Read more14th January 2019
Researchers from our Centre for Haemato-Oncology attended the 60th American Society of Hematology (ASH) Annual Meeting and Exposition to showcase our blood cancer research.
Read more30th November 2018
November is Lung Cancer Awareness Month. Lung cancer is one of the main cancer types on which research is focused here at the Barts CRUK Centre.
Read more17th October 2018
Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC).
Read more12th September 2018
BCI held the 2018 VOICE (Vision On Information, Confidence & Engagement) course- a study week that aims to take patient advocates from bedside to bench by providing an introduction to basic cancer biology, research terminology and study design.
Read more15th June 2018
Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.
Read more